Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial

Obstet Gynecol. 2008 Feb;111(2 Pt 1):267-77. doi: 10.1097/01.AOG.0000298338.58511.d1.

Abstract

Objective: To understand if the contraceptive ring or patch was more acceptable, as measured primarily by continuation, to women using an oral contraceptive and interested in a nondaily, combined hormonal contraceptive.

Methods: Five hundred women were randomly assigned to use the contraceptive ring (n=249) or contraceptive patch (n=251) for four consecutive menstrual cycles, starting with their next menses. Participants returned for a single follow-up visit during the fourth cycle for an evaluation, which included a questionnaire to assess acceptability and adverse effects.

Results: Rates of completion of three cycles were 94.6% (95% confidence interval [CI] 91.0-97.1%) and 88.2% (95% CI 83.4-92.0%) for ring and patch users, respectively (P=.03). Of these women, 71.0% (95% CI 64.8-76.6%) and 26.5% (95% CI 21.0-32.6%), respectively, planned to continue their method after the study (P<.001). Women switching to the patch were significantly more likely than women switching to the ring to experience longer periods (38% compared with 9%), increased dysmenorrhea (29% compared with 16%), frequent nausea (8% compared with 1%), frequent mood swings (14% compared with 8%), and frequent skin rash (12% compared with 2%) and were less likely to experience frequent vaginal discharge (8% compared with 17%). Ring users preferred the ring to the oral contraceptive (P<.001), and patch users preferred the oral contraceptive to the patch (P<.001). Nugent scores increased only in patch users (P=.01), although most of these women were asymptomatic.

Conclusion: Women satisfied with combined oral contraceptives and interested in a nondaily method are more likely to continue using the contraceptive ring than the contraceptive patch.

Clinical trial registration: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00269620.

Level of evidence: I.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intravaginal
  • Adult
  • Contraception / methods*
  • Contraceptive Agents, Female* / adverse effects
  • Contraceptive Devices, Female* / adverse effects
  • Drug Implants*
  • Female
  • Follow-Up Studies
  • Humans
  • Menstruation / drug effects
  • Menstruation / physiology*
  • Menstruation Disturbances / epidemiology*
  • Menstruation Disturbances / etiology
  • Patient Acceptance of Health Care
  • Patient Compliance
  • Patient Satisfaction

Substances

  • Contraceptive Agents, Female
  • Drug Implants

Associated data

  • ClinicalTrials.gov/NCT00269620